STOCK TITAN

Assembly Bioscie - ASMB STOCK NEWS

Welcome to our dedicated page for Assembly Bioscie news (Ticker: ASMB), a resource for investors and traders seeking the latest updates and insights on Assembly Bioscie stock.

Assembly Biosciences, Inc. (ASMB) is a clinical-stage biotechnology leader advancing innovative oral therapies for hepatitis B virus (HBV) and microbiome-related disorders. This news hub provides investors and researchers with timely updates on clinical developments, regulatory milestones, and strategic initiatives.

Access authoritative reporting on ASMB's antiviral research programs and microbiome therapeutic platforms. Our curated news collection features press releases covering clinical trial progress, partnership announcements, and scientific presentations - all essential for informed analysis of the company's pipeline.

Key focus areas include updates on HBV core inhibitor candidates, microbiome strain development, and intellectual property advancements. Content is rigorously verified to ensure compliance with financial disclosure standards while maintaining scientific accuracy.

Bookmark this page for direct access to primary source materials and objective reporting on ASMB's pioneering work in oral antiviral therapies. Check regularly for the latest developments in this dynamic sector of precision medicine.

Rhea-AI Summary
Assembly Biosciences, Inc. (Nasdaq: ASMB) announced new data from its virology portfolio at the American Association for the Study of Liver Diseases (AASLD), highlighting the potential of its preclinical IFNAR agonist program to improve tolerability and the results of vebicorvir in combination with Nrtl and AB-729 in virologically suppressed patients with hepatitis B e antigen negative chronic HBV.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none
-
Rhea-AI Summary
Assembly Biosciences, Inc. (ASMB) has partnered with Gilead Sciences to develop treatments for herpesviruses, HBV, and HDV, with 4 candidates expected in clinical development by the end of 2024. The $100 million upfront payment and investment from Gilead extends cash runway into 2H 2025.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-11.76%
Tags
-
Rhea-AI Summary
ASMB: Assembly Biosciences Announces Dr. Anuj Gaggar as Chief Medical Officer, Bringing Infectious Disease Expertise to Antiviral Programs
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-4.49%
Tags
none
Rhea-AI Summary
Gilead Sciences and Assembly Biosciences have entered into a 12-year partnership to develop antiviral therapies for herpesviruses, hepatitis B virus (HBV), and hepatitis D virus (HDV). Assembly Bio will receive $100 million upfront payment, including an equity investment. Gilead may opt-in for exclusive rights to Assembly Bio's programs and could purchase up to 29.9% of Assembly Bio's voting stock. Assembly Bio may receive up to $330 million per program in potential milestones and royalties. Gilead's EPS is expected to be reduced by $0.05 - $0.07 in 2023.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
71.23%
Tags
partnership
-
Rhea-AI Summary
Assembly Biosciences to present preclinical and clinical data at AASLD
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.37%
Tags
conferences
-
Rhea-AI Summary
Assembly Biosciences selects development candidate ABI-6250 for IND-enabling studies targeting chronic hepatitis D virus (HDV) infection
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-4.49%
Tags
none
Rhea-AI Summary
Assembly Biosciences to present new data on hepatitis B and hepatitis D pipeline programs at the 2023 International HBV Meeting
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.19%
Tags
none
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.94%
Tags
-
Rhea-AI Summary
Assembly Biosciences, Inc. (Nasdaq: ASMB) announced preclinical data on ABI-5366, a long-acting herpes simplex virus (HSV) helicase inhibitor for high-recurrence genital herpes. The data showed potent antiviral activity against both HSV-1 and HSV-2, sustained plasma concentrations, and a favorable safety profile. The company plans to enter the clinic in the first half of 2024.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
4.63%
Tags
none
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
4.67%
Tags
none
Assembly Bioscie

Nasdaq:ASMB

ASMB Rankings

ASMB Stock Data

75.26M
6.73M
12.15%
50.33%
0.32%
Biotechnology
Pharmaceutical Preparations
Link
United States
SOUTH SAN FRANCISCO